TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00755235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression care management by secure messaging
Description: Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
Study: NCT03367780

Intervention type: DEVICE
Intervention: PSMA PET/CT-scan
Description: PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.
Study: NCT01665404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Multiple doses of fluvoxamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Single dose of RO4917523
Study: NCT03620981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Drug: 1 tablet /day Once daily for 10 weeks
Study: NCT03654989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil iontophoresis
Description: We will administer treprostinil at increasing doses by a iontophoresis.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Remodulin® placebo iontophoresis
Description: Placebo iontophoresis will be performed using Remodulin® placebo (United Therapeutics) delivered with Axion GmbH electrodes connected to a PeriIont generator (Perimed).~* Part 1: 1 administration/day, on separate days, with 72h between two doses. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~* Part 2: 1 administration/day for 10 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².
Study: NCT04121221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA Depot
Description: Long acting intramuscular injection of glatiramer acetate, once every 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM injection once every 4 weeks
Study: NCT01551836

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol formulation 1
Description: formulation 1

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol formulation 2
Description: Formulation 2
Study: NCT00950209

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: saline infusion
Description: In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: saline infusion
Description: In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: saline infusion
Description: In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48
Study: NCT03620981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Drug: 1 tablet /day Once daily for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1 tablet /day Once daily for 10 weeks
Study: NCT04355832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1
Description: Infusion of Glucagon-like peptide-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Infusion of normal saline solution that will mimic Glucagon-like peptide-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Infusion of normal saline solution that will mimic Glucagon-like peptide-1
Study: NCT04158258

Intervention type: DRUG
Intervention: Bevacizumab
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Trastuzumab
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Ado-trastuzumab emtamsine
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Pertuzumab
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Atezolizumab
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Capecitabine
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Study: NCT00950209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: euglycaemic hyperinsulinic clamp
Description: an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l
Study: NCT03731000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHIL® device
Description: Using PHIL® device for treatment of intracranial dural arteriovenous fistulas
Study: NCT05673902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Study: NCT04003142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral Tablet
Study: NCT04303169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days
Study: NCT00950209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: euglycaemic hyperinsulinic clamp
Description: an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: infusion of Endolipide and heparin
Description: an infusion with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperglycaemic hyperinsulinic clamp
Description: a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.
Study: NCT04415593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose of peanuts
Description: Patients will receive a high dose of ground peanuts (300 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of peanuts
Description: Patients will receive a low dose of ground peanuts (150 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
Study: NCT01387646

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project IMAGE
Description: Participants in the intervention arm will be interviewed at baseline, given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and enrolled in the intervention. The intervention will include 2 workshops, 5 support groups sessions and 2 individual counseling sessions. They will be interviewed and examined again after completing the intervention, to establish a post-intervention baseline.
Study: NCT04365413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSOT Device
Description: The MSOT Device will be used to take images of the tumor and/or lymph nodes of patients with solid tumors before and after surgery to measure the margins of the tumor and/or positive lymph node.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature Measurement
Description: The temperature of the skin will be measured prior to and after MSOT imaging.
Study: NCT00714233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 425mg. capsules, 2 capsules BID x 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pills (Yasmin)
Description: Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Description: weekly classes x 24 weeks for training in diet, exercise and behavior modification skills

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to the active metformin arm. 2 capsules BID x 24 weeks.
Study: NCT01568190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVANZ MITE
Description: Immunotherapy Dermatophagoides mix
Study: NCT00690716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal CO2
Description: Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo
Description: Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
Study: NCT01190657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selbex
Description: 50mg/day, 3 times/day, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selbex
Description: 50mg/day, 3 times/day, for 56 days
Study: NCT01666444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)
Study: NCT03803917

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Injection with freshly collected autologous adipose tissue
Study: NCT01241578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Participants receive instructions for making healthy changes to their diet and physical activity habits.
Study: NCT01666444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin (PLD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX-2337
Description: TLR8 Agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT01761955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Dairy
Description: Consuming 4 or more servings of dairy products per day for a period of 6 months
Study: NCT01861340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Dexamethasone, and MEDI-551
Description: Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
Study: NCT01665404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Single dose of RO4917523
Study: NCT03860441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training
Description: Intervention used CogniFit platform with Personalized brain training sub-option
Study: NCT00914199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: Implantation of coronary stent in bifurcation lesion.
Study: NCT02786979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral
Study: NCT03860441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: Intervention used CogniFit platform with Personalized brain training sub-option
Study: NCT00214682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folate (400mcg) and Vitamin B12 (100 mcg)
Description: The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
Study: NCT00797459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane and Restylane-L
Description: This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
Study: NCT04107857

Intervention type: BEHAVIORAL
Intervention: ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer
Description: * Brief advise to quit smoking~* Referral to Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov

Intervention type: BEHAVIORAL
Intervention: ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer
Description: -Nicotine replacement therapy, varenicline, bupropion, or combination therapy (not provided by study)

Intervention type: BEHAVIORAL
Intervention: Data Driven Feedback reports
Description: -Feedback reports will be based on data
Study: NCT03282201

Intervention type: OTHER
Intervention: Transfusion
Description: Transfusion of red blood cells, fresh frozen plasma, platelets
Study: NCT01166659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent
Description: The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
Study: NCT04227249

Intervention type: PROCEDURE
Intervention: no lymph node dissection
Description: do not undergo lymph node dissection
Study: NCT02786979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral
Study: NCT04638699

Intervention type: OTHER
Group type: OTHER
Intervention: OptiScreen training
Description: Special psycho-oncological training for nursing staff to acquire basic knowledge about the experience of mental stress as well as diagnostics of psychosocial stress
Study: NCT04255875

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07209326
Description: Participants will receive SC or IV single ascending doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07209326
Description: SCD participants will receive a multiple dose of subcutaneous PF-07209326
Study: NCT03029338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T cells
Description: CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
Study: NCT02927769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: Specified Dose on Specified Days
Study: NCT03169361

Intervention type: DRUG
Intervention: Ixazomib
Description: Ixazomib capsules
Study: NCT02402972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUDR +oxaliplatin
Description: IPC: one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin+Leucovorin+5-FU
Description: Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin+Leucovorin+5-FU
Description: Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
Study: NCT01537653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR231893 (REGN668)
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR231893 (REGN668)
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR231893 (REGN668)
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
Study: NCT01537653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR231893 (REGN668)
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
Study: NCT00214682

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pain and arthritis management information
Description: Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
Study: NCT01537653

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
Study: NCT03242928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: 50 mg and 100 mg tablets taken orally
Study: NCT00438750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Independent Excercises
Description: Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
Study: NCT03242928

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets taken orally BID
Study: NCT04541849

Intervention type: OTHER
Intervention: Critical Care
Description: Critical care in the intensive care units
Study: NCT03409315

Intervention type: PROCEDURE
Intervention: Centralized Therapeutic Drug Monitoring
Description: Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.

Intervention type: PROCEDURE
Intervention: Centralized Therapeutic Drug Monitoring
Description: Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.
Study: NCT02394444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triadic parent-infant Relationship Therapy (TRT)
Description: 22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
Study: NCT01099839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglitol
Description: oral
Study: NCT02024711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYEFILL® C.-US Viscoelastic
Description: EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healon® Viscoelastic (CONTROL)
Description: Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
Study: NCT04280601

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: vitamin D
Description: Patients with insufficient and/or deficient vitamin D status (\<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months
Study: NCT00003546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8 Gy to tumor bed
Study: NCT03357276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mix vaccine
Description: Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
Study: NCT03299517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiarrythmic Drugs
Description: Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Description: Patient will be randomly randomized 1: 1 for the the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.